Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/37049
Title: Glabridin attenuates airway inflammation and hyperresponsiveness in a mice model of ovalbumin-induced asthma
Authors: Doğan, Muhammed Fatih
Parlar, A.
Cam, S.A.
Tosun, E.M.
Uysal, F.
Arslan, S.O.
Keywords: Asthma
Glabridin
Ovalbumin
Plethysmography
aluminum hydroxide
dexamethasone
glabridin
immunoglobulin E
methacholine
ovalbumin
protein
aerosol
animal experiment
animal model
animal tissue
Article
asthma
body plethysmography
breathing rate
bronchoalveolar lavage fluid
controlled study
dose response
drug dose comparison
drug efficacy
drug mechanism
drug megadose
eosinophil
expiratory reserve volume
immunoglobulin blood level
leukocyte count
leukocyte differential count
low drug dose
lung function
lymphocyte
male
monocyte
mouse
neutrophil
nonhuman
ovalbumin-induced airway inflammation
peak expiratory flow
peak inspiratory flow
priority journal
respiratory tract allergy
tidal volume
Publisher: Academic Press
Abstract: Asthma is an inflammatory disease of the airways of the lungs, which is characterized by airflow obstruction and bronchospasms. Glabridin is a major flavonoid, especially found in root of Glycyrrhiza glabra, and has several pharmacological activities, including antioxidant and anti-inflammatory effects. The anti-asthmatic effect and possible mechanism of glabridin, however, have not been revealed so far. The aim of this study is to investigate the effects and possible mechanisms of glabridin against ovalbumin (OVA)-induced airway hyperresponsiveness (AHR) and inflammation in mice. In male BALB/c mice, asthma was induced by intraperitoneal (i.p) injection of OVA mixed with 2 mg aluminium hydroxide on days 0, 14 and boosted with OVA aerosol challenge on days 21, 22, and 23. Mice were either treated with dexamethasone (i.p, 1 mg/kg) or glabridin (10, 20, and 30 mg/kg) from days 18–23. Pulmonary function parameters such as peak inspiratory flow, peak expiratory flow, tidal volume, expiratory volume, the frequency of breathing, enhanced pause values were evaluated by using whole-body plethysmography. Measurements were performed at baseline and following methacholine (50 mg/mL) challenges. In addition, white blood cells (WBC) count, total protein, and IgE levels were measured in bronchial alveolar lavage fluid (BALF), lung, and serum, respectively. Glabridin (20 or 30 mg/kg) significantly attenuated (p < 0.05) OVA-induced alteration in respiratory parameters. Elevated counts of total WBC, differential WBC (neutrophils, lymphocytes, monocytes, and eosinophils) in BALF and the total protein in lungs and BALF were significantly decreased (p < 0.05) by glabridin (20 or 30 mg/kg). It also significantly attenuated the increased serum IgE levels (p < 0.05). As glabridin reduces the level of serum IgE, the total protein and the count of WBC and improves respiratory function, it may be a novel therapeutic agent in asthma. © 2020 Elsevier Ltd
URI: https://hdl.handle.net/11499/37049
https://doi.org/10.1016/j.pupt.2020.101936
ISSN: 1094-5539
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

28
checked on Nov 16, 2024

WEB OF SCIENCETM
Citations

21
checked on Nov 16, 2024

Page view(s)

42
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.